BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 02:18 pm EDT
Share
BioAdaptives, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.004322 million compared to USD 0.006065 million a year ago. Net loss was USD 0.223837 million compared to USD 0.309246 million a year ago.
For the six months, sales was USD 0.009855 million compared to USD 0.010583 million a year ago. Net loss was USD 0.590968 million compared to USD 0.801149 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.
BioAdaptives, Inc. manufactures and distributes natural plant and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore. It also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include an Equine All-in-One and Equine All-In-One Plus formulation, which it markets to trainers, horse owners and boarding stables, and a Canine All-in-One.
BIOADAPTIVES, INC. 
